Using malaria prevention methods to also tackle malnutrition in children
Leveraging the seasonal malaria chemoprevention platform to address malaria and malnutrition
This study is looking at how giving kids aged 3 to 59 months in Burkina Faso special malaria medicine during the rainy season can help not only prevent malaria but also improve their nutrition and health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11053897 on NIH RePORTER |
What this research studies
This research investigates how seasonal malaria chemoprevention (SMC) can be utilized not only to prevent malaria but also to address malnutrition in children aged 3-59 months during the rainy season in Burkina Faso. The approach involves the monthly distribution of antimalarial medications, sulfadoxine-pyrimethamine and amodiaquine, to children at risk of both malaria and malnutrition. By leveraging the existing SMC platform, the study aims to evaluate the effectiveness of additional interventions that could improve child health outcomes during this critical period. The research will assess whether these combined efforts can enhance weight gain and reduce the incidence of malaria-related illnesses in children.
Who could benefit from this research
Good fit: Ideal candidates for participation are children aged 3-59 months living in areas of Burkina Faso where malaria and malnutrition are prevalent.
Not a fit: Patients outside the targeted age range or those not residing in the affected regions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved health outcomes for children by reducing both malaria incidence and malnutrition rates.
How similar studies have performed: Previous research has shown that antimalarial treatments can positively impact weight gain in malnourished children, indicating potential success for this combined approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Oldenburg, Catherine Elizabeth — University of California, San Francisco
- Study coordinator: Oldenburg, Catherine Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.